A new study used flow cytometry to compare phosphorylation levels of intracellular epitopes in peripheral blood mononuclear cells from patients with psoriasis in clinical remission who were treated with reference infliximab versus healthy controls, and further evaluated whether a switch from reference infliximab to biosimilar CT-P13 affected intracellular phosphorylation patterns.
Biologic treatments, including anti—tumor necrosis factor (anti-TNF) agents, can significantly improve psoriasis, but come at a high cost. While biosimilar therapies help to control the cost of biologic treatment, differences in manufacturing of innovator biologics and biosimilars have raised concerns about the potential to impact biological activity, efficacy, and tolerability.
A new study, published in the British Journal of Dermatology, used flow cytometry to compare phosphorylation levels of intracellular epitopes in peripheral blood mononuclear cells (PBMC) from patients with psoriasis in clinical remission (n = 25) who were treated with reference infliximab versus healthy controls (n = 19), and further evaluated whether a switch from reference infliximab to biosimilar CT-P13 affected intracellular phosphorylation patterns.
The researchers, led by Anders Krough Aarebrot, measured phosphorylation in PBMC before and after TNF stimulation in cells collected at inclusion, 3 months, and 12 months. Twenty-two patients were then randomized to either continue treatment with reference infliximab or switch to CT-P13.
The researchers found that:
The authors concluded that although there were significant differences in intracellular phosphorylation of PBMC between patients with psoriasis and healthy controls, a switch to biosimilar infliximab did not result in any significant differences, a finding that suggests that CT-P13 is noninferior to its reference.
The researchers note that this is the first study to use flow cytometry in PBMC comparing patients with psoriasis with healthy controls, or to monitor patients switching from biologics to biosimilars; they suggest that using flow cytometry might represent a promising tool to monitor disease activity and treatment efficacy in patients with psoriasis in the future.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Promising Results for Ustekinumab, Adalimumab Biosimilars Presented at AAD
March 18th 2025Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved interchangeable with reference adalimumab, according to posters at the American Academy of Dermatology (AAD) annual meeting.